STERIS plc’s Stock Price Takes a Dip, Falling to $220.67 with a 3.64% Decrease: Time to Invest?

STERIS plc (STE)

220.67 USD -8.33 (-3.64%) Volume: 0.7M

STERIS plc’s stock price currently stands at 220.67 USD, experiencing a trading session drop of -3.64%, despite a minimal year-to-date increase of +0.37%, with a trading volume of 0.7M. This performance reflects the dynamic nature of STE’s stock market journey.

Latest developments on STERIS plc

STERIS plc (NYSE:STE) has seen a strong trading day, outperforming competitors, driven by key financial players. Raymond James & Associates expanded their holdings, contributing to their $160.13 million stake in the company, while Dynamic Advisor Solutions LLC also increased their investment. Financiere des Professionnels Fonds d’investissement inc. added to the momentum by purchasing more shares. The Q1 earnings of STERIS also surpassed estimates, leading to a consensus rating of “Moderate Buy” from brokerages, with a set price target of $239.60.

A look at STERIS plc Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

The long-term outlook for STERIS is looking favorable, according to the Smartkarma Smart Scores. With an overall score of 3 out of 5, the company is expected to perform well in the future. This is based on its strong momentum score of 4, indicating that the company is currently on a positive trajectory.

STERIS is a provider of infection prevention and other procedural products and services, serving the healthcare, pharmaceutical, and medical device industries. The company has received a score of 2 for both value and resilience, suggesting that it may be undervalued and has a strong ability to weather potential challenges. Additionally, STERIS has received a score of 3 for growth, indicating that it has potential for future expansion and success in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma